Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


13 Items
Title  Creator  Group name  Publishing year 
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort Galvin et al. EquipeCTCS 2024-01
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort Grinda et al. EquipeCTCS 2023-08
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study François-Martin et al. EquipeELC 2023-02-13
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study Falandry et al. EquipePC 2022-03
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial Bidard et al. EquipePC 2022-11
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer Delaloge et al. EquipePC 2022-05
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations Jacot et al. EquipeCTCS 2022-11
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study Dalenc et al. EquipeELC 2022-03
Emotional processes in partners' quality of life at various stages of breast cancer pathway: a longitudinal study Baudry et al. EquipeELC 2022-11-24
Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France de Calbiac et al. EquipePC 2022-09-01
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes Carausu et al. EquipeELC 2022-12-01
Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress Baudry et al. EquipeELC 2022-01-05
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases Jacot et al. EquipeELC 06 2016
13 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés